Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mineralys Therapeutics, Inc. (Nasdaq: MLYS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor, through clinical development. As a clinical-stage biopharmaceutical company focused on hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other aldosterone-driven diseases, Mineralys uses SEC filings to report financial results, capital-raising activities and other material events.
Current and prospective investors can review Form 8-K filings where Mineralys reports quarterly financial results and corporate updates, as well as transactions such as underwritten public offerings of common stock and changes to at-the-market equity programs. These documents often reference the company’s clinical progress with lorundrostat, including pivotal trials like Launch-HTN and Advance-HTN, Phase 2 programs such as Explore-CKD and Explore-OSA, and steps toward a potential New Drug Application (NDA) with the U.S. Food and Drug Administration.
Over time, the filings set is expected to include annual reports on Form 10-K, quarterly reports on Form 10-Q, and additional 8-Ks that elaborate on risk factors, liquidity, research and development spending, and the company’s dependence on the success of lorundrostat and key licensing arrangements. Investors may also monitor registration statements and prospectus supplements related to equity offerings, as reflected in referenced Form S-3 filings.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points, such as trial-related disclosures, financing terms and forward-looking statements. Real-time updates from EDGAR, combined with tools to track items like material events and offering details, help users quickly understand how Mineralys Therapeutics’ regulatory and financial reporting aligns with its clinical and regulatory strategy for lorundrostat.
Mineralys Therapeutics, Inc. insider plans another stock sale under Rule 144. A person identified as Jon Congleton has filed to sell 16,236 shares of Mineralys common stock through Merrill Lynch on or about 01/12/2026 on the NASDAQ, with an indicated aggregate market value of $529,639.50. These shares were acquired on 01/10/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan.
The notice also reports prior sales of Mineralys common stock during the past three months by the same seller, including 15,100 shares on 10/13/2025 for gross proceeds of $644,326.47 and 200,000 shares on 11/11/2025 for gross proceeds of $9,088,502.77. The filing lists 79,139,956 Mineralys common shares outstanding, providing context for the size of the planned sale.
Mineralys Therapeutics, Inc. insider David Rodman has filed a notice to sell 2,170 shares of common stock through Merrill Lynch on or about 01/09/2026 on the NASDAQ, with an aggregate market value of $72,195.90. These shares were acquired the same day via a broker-assisted cashless exercise of employee stock options. The filing also lists prior sales over the past three months, including 192,715 shares sold on 01/05/2026 for $6,749,100.06, 70,037 shares sold on 01/02/2026 for $2,511,919.03, and 10,369 shares sold on 10/15/2025 for $445,982.61. Shares of Mineralys Therapeutics outstanding were 79,139,956 around the time of the planned sale.
Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reportedmultiple stock option exercises and related share sales in early January 2026. On January 2, 2026, he exercised options for 10,053, 3,629, 9,347, 20,168 and 24,193 shares of common stock at exercise prices of $1.08, $15.44, $10.20, $16.00 and $14.25, respectively, then sold 70,037 shares at a weighted-average price of $35.8656.
On January 5, 2026, he exercised additional options for 28,038, 10,121, 26,069, 53,630 and 67,473 shares at the same exercise prices, and sold 139,245 shares at a weighted-average price of $34.8275 and 53,470 shares at a weighted-average price of $35.5256. Following the last reported transaction, he directly owned 61,804 common shares, which includes 680 shares purchased under the 2023 Employee Stock Purchase Plan that were not previously reported. All transactions were effected under a Rule 10b5-1 trading plan adopted on October 6, 2025.
Mineralys Therapeutics (MLYS) reported that its Chief Executive Officer and director exercised stock options for 24,082 shares of common stock on 11/21/2025 at an exercise price of $0.54 per share.
Following this transaction, the CEO directly holds 655,387 shares of Mineralys common stock. The filing also clarifies that the option’s exercise price was previously shown as $0.53 per share due to a rounding error in an earlier Form 3, and notes that the option vested 25% on March 12, 2022, with the remainder vesting in 36 substantially equal monthly installments.
Mineralys Therapeutics, Inc. (MLYS) reported an insider transaction by a major shareholder group associated with Catalys Pacific. On 11/20/2025, an indirect holder reported the sale of 1,000,000 shares of Mineralys common stock at $43.35 per share, coded as an "S" transaction, which indicates a sale.
After this transaction, the reporting entities collectively reported 7,903,838 shares of Mineralys common stock beneficially owned on an indirect basis. The filing identifies the reporting persons as including a director and a 10% owner, with the shares held of record by Catalys Pacific Fund, LP and controlled through its general partner structure. The related entities and Brian Taylor Slingsby state that they may be deemed to have voting and investment power over these shares but disclaim beneficial ownership except to the extent of any pecuniary interest.
Mineralys Therapeutics (MLYS) Form 4: CFO and Secretary reported option exercises and share sales on 11/11/2025. He exercised options for 20,547 shares at $10.2, 34,414 at $16, 44,079 at $14.25, and 6,613 at $15.44. Same day, he executed multiple open-market sales, including 38,900 shares at a weighted-average price of $45.9277 and 32,718 at $46.8848, with other sales reported at weighted-average prices between $41.6522 and $46.8848.
Following the transactions, he directly beneficially owned 19,396 shares. The filing also notes that since his last ownership report, 83,598 shares were transferred to an ex-spouse pursuant to a domestic relations order.
Mineralys Therapeutics, Inc. (MLYS) reported insider activity on a Form 4. The company’s Chief Executive Officer and director sold 200,000 shares of common stock on 11/11/2025 in multiple transactions at weighted‑average prices that include $41.6395, $42.3095, $43.4959, $45.2003, $45.8335, and $46.8862. Footnotes disclose execution price ranges spanning $41.0500 to $47.4191 for the respective trades.
After these sales, the reporting person beneficially owns 631,305 shares, held directly. This filing lists the transactions as open‑market sales with weighted‑average pricing and provides to interested parties the availability of detailed trade‑by‑trade breakdowns upon request.
Mineralys Therapeutics (MLYS) director reports option exercise and same-day sales. On 11/13/2025, the reporting person exercised 15,000 stock options at $10.20 per share, received 15,000 common shares, and sold them in two tranches at weighted-average prices of $45.8083 and $46.3554.
The sales totaled 10,115 shares at $45.8083 and 4,885 shares at $46.3554, resulting in 0 common shares held directly after the transactions. Following the exercise, 17,900 stock options remained beneficially owned, with the option grant expiring on 02/13/2035 and vesting in 12 monthly installments following the grant date.
Mineralys Therapeutics director reports option exercises and share sales. A company director filed a Form 4 showing multiple stock option exercises on November 11–13, 2025 at exercise prices of $10.20 and $12.69 per share, followed by same-day open market sales of the resulting common shares at prices around $42.43–$47.28.
After these transactions, the reporting person held no shares of common stock directly, but continued to hold 34,000 stock options with exercise prices of $10.20 and $12.69, expiring in 2034 and 2035 and vesting in monthly installments.
Mineralys Therapeutics (MLYS) filed its third‑quarter 2025 report, highlighting progress toward an NDA for lorundrostat and a strengthened balance sheet. The company completed two pivotal hypertension trials (Launch‑HTN and Advance‑HTN) that achieved statistical significance and plans to submit an NDA in late 2025 or during the first quarter of 2026.
Cash, cash equivalents, and investments totaled $593.6 million as of September 30, 2025. For the quarter, basic and diluted net loss per share was $0.52. For the nine months ended September 30, 2025, net loss was $122.4 million.
Mineralys raised capital through two underwritten offerings—$269.6 million in September 2025 and $188.7 million in March 2025—and an ATM program totaling $27.3 million in net proceeds before terminating the ATM in November 2025. These funds support clinical development, manufacturing, pre‑commercialization, and general corporate purposes. Common shares outstanding were 79,139,956 as of November 3, 2025.